Search
Terguride
go.drugbank.com/drugs/DB13399ExperimentalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCarbutamide
go.drugbank.com/drugs/DB13406InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesRokitamycin
go.drugbank.com/drugs/DB13409ExperimentalCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsDiisopromine
go.drugbank.com/drugs/DB13476ExperimentalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesIproniazid
go.drugbank.com/drugs/DB04818ApprovedWithdrawnWithdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsTienilic acid
go.drugbank.com/drugs/DB04831ApprovedWithdrawnTienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension. It was withdrawn in 1982 after case reports in the United States suggested a link between ticrynafen an...
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsMethaqualone
go.drugbank.com/drugs/DB04833ApprovedIllicitWithdrawnMethaqualone is a sedative-hypnotic drug that is similar in effect to barbiturates, a general central nervous system depressant. The sedative-hypnotic activity was first noted by Indian researchers in the 1950s and in 1962 methaqualone i...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCyproterone acetate
go.drugbank.com/drugs/DB04839ApprovedInvestigationalAn anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estroge...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsIxabepilone
go.drugbank.com/drugs/DB04845ApprovedInvestigationalIxabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors